Former Teva CEO Levin to Lead Startup Biotech

Apr 16, 2015

Bloomberg

Jeremy Levin, who was pushed from his CEO position at Teva Pharmaceutical in late 2013 after a disagreement with the board, has announced his intentions to serve as CEO for a U.S. biotech startup focused on brain diseases.

NY-based Ovid Therapeutics will license a drug for two rare brain diseases from Copenhagen-based H. Lundbeck A/S.

“Expect us to do more licensing agreements focused initially on orphan and rare diseases,” Levin said. “We also have our own in-house research and development, and as we grow, we will acquire outright products that are of value.” 

Read the Bloomberg release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments